Skip to content
Search this website
Main menu
Home
Tumour Sites
Acute Oncology & Cancer of Unknown Primary (CUP)
National Awareness and Early Diagnosis
Sub Groups or Cross Cutting Groups
Terms of Reference
Tumour Site Specific Information
Medicines & Prescribing
Network Chemotherapy Prescription Proformas/Protocols (NHS Staff use)
Oncological Treatment Guidelines
SACT Pathways, Guidelines for the Management of SACT Induced Adverse Reactions and Nursing
Aria documents
Patients, Carers & Community
NHS Hospital Cancer Services
Hospice Information
Information and support
KM-Cancer Action Partnership and Cancer Action Groups
Patient and carers calendar
Newsletters
You Said, We Did
About us
Kent & Medway Cancer Collaborative (KMCC)
.
Myeloma Proformas and Protocols
HAEM-MYEL-032 MPV (sub cut - weekly) v1
HAEM-MYEL-033 Carfilzomib for multiple myeloma v2
HAEM-MYEL-035 Ixazomib with Lenalidomide and Dexamethasone v2
HAEM-MYEL 036 Daratumumab v2
HAEM-MYEL-037 Daratumumab in combination with bortezomib and dexamethasone v2
HAEM-MYEL-038 Daratumumab in combination with bortezomib and dexamethasone (weekly) v2
HAEM-MYEL-039 EAMS Isatuximab, pomalidomide and dexamethasone v1
HAEM-MYEL-039 Isatuximab, pomalidomide and dexamethasone v2
HAEM-MYEL-040 Daratumumab SC v1
HAEM-MYEL-041 Daratumumab SC in combination with bortezomib (D1, 4, 8 & 11) and dexamethasone v1
HAEM-MYEL-042 Daratumumab SC in combination with bortezomib and dexamethasone (weekly) v1
Links for Prescription Authorisation Forms
Revlimid
Thalidomide Celgene
Related content
Network Chemotherapy Prescription Proformas/Protocols (NHS Staff use)
Haem - Myeloma Proformas
